Jiang Daisong, Yue Honghua, Liang Wei-Tao, Wu Zhong
Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Front Physiol. 2024 Aug 9;15:1347888. doi: 10.3389/fphys.2024.1347888. eCollection 2024.
Developmental Endothelial Locus-1 (DEL-1), also known as EGF-like repeat and discoidin I-like domain-3 (EDIL3), is increasingly recognized for its multifaceted roles in immunoregulation and vascular biology. DEL-1 is a protein that is mainly produced by endothelial cells. It interacts with various integrins to regulate the behavior of immune cells, such as preventing unnecessary recruitment and inflammation. DEL-1 also helps in resolving inflammation by promoting efferocytosis, which is the process of clearing apoptotic cells. Its potential as a therapeutic target in immune-mediated blood disorders, cardiovascular diseases, and cancer metastasis has been spotlighted due to its wide-ranging implications in vascular integrity and pathology. However, there are still unanswered questions about DEL-1's precise functions and mechanisms. This review provides a comprehensive examination of DEL-1's activity across different vascular contexts and explores its potential clinical applications. It underscores the need for further research to resolve existing controversies and establish the therapeutic viability of DEL-1 modulation.
发育性内皮位点-1(DEL-1),也被称为表皮生长因子样重复序列和盘状结构域蛋白1样结构域-3(EDIL3),因其在免疫调节和血管生物学中的多方面作用而日益受到认可。DEL-1是一种主要由内皮细胞产生的蛋白质。它与多种整合素相互作用,以调节免疫细胞的行为,例如防止不必要的募集和炎症反应。DEL-1还通过促进胞葬作用(即清除凋亡细胞的过程)来帮助解决炎症。由于其在血管完整性和病理学方面的广泛影响,DEL-1作为免疫介导的血液疾病、心血管疾病和癌症转移的治疗靶点的潜力已受到关注。然而,关于DEL-1的确切功能和机制仍有未解决的问题。本综述全面考察了DEL-1在不同血管环境中的活性,并探讨了其潜在的临床应用。它强调了进一步研究以解决现有争议并确定DEL-1调节的治疗可行性的必要性。